No of participants | 72 | 35 | 37 |
Mean (SD) age (years) | 47.9 (8.9) | 48.4 (8.4) | 47.5 (9.4) |
Male, n (%) | 33 (46) | 16 (46) | 17 (46) |
Mean (SD) BMI (kg/m2) | 26.8 (7.6) | 25.6 (4.5) | 28.0 (9.6) |
Mean (SD) duration of asthma (years) | 26.3 (14.1) | 24.5 (14.4) | 28.0 (13.7) |
Median (range) daily inhaled steroid dose (μg)* | 400 (100–2000) | 400 (100–2000) | 400 (200–1000) |
Number on long acting β2 agonists | 19 | 7 | 12 |
Mean (SD) FEV1 (l) | 2.51 (0.66) | 2.48 (0.61) | 2.53 (0.71) |
Mean (SD) FEV1 (% predicted) | 77 (16) | 78 (17) | 77 (15) |
Geometric mean (SD) PD20 | 0.77 (4.55) | 0.86 (4.63) | 0.69 (4.53) |
Mean (SD) morning PEF (l/min) | 416 (77) | 416 (65) | 416 (88) |
Median (range) daily bronchodilator use (puffs/24 hours) | 0 (0–12) | 0 (0–12) | 0 (0–12) |
Median (range) daytime symptom score | 0 (0–3) | 0 (0–3) | 0 (0–2) |
Median (range) night time symptom score | 0 (0–2) | 0 (0–2) | 0 (0–2) |
Mean (SD) vitamin E intake (mg) | 7.27 (3.55) | 6.84 (2.50) | 7.66 (4.29) |
Mean (SD) serum vitamin E (μmol/l) | 26.8 (8.2) | 27.4 (10.4) | 26.1 (5.4) |